Assessing the abuse potential of methylphenidate in nonhuman and human subjects : A review

Pharmacology Biochemistry and Behavior

Volumn 68, Issue 3, 2001, Pages 611-627

  Kollins, Scott H ^a   MacDonald, Emily K ^b   Rush, Craig R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Drug abuse; Drug reinforcement; Drug discrimination; Methylphenidate; Subjective effects

Indexed keywords

AMPHETAMINE; COCAINE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MISUSE; DRUG SELF ADMINISTRATION; HUMAN; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; REVIEW;

ANIMALS; DOPAMINE UPTAKE INHIBITORS; HUMANS; METHYLPHENIDATE; SUBSTANCE-RELATED DISORDERS;

EID: 0035007998     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(01)00464-6     Document Type: Article

References (111)

1. Aigner TG, Balster RL. Rapid substitution procedure for intravenous drug self-administration studies in rhesus monkeys. Pharmacol, Biochem Behav 1979;10:105-12.
2. Altmann J, Everitt BJ, Glautier S, Markou A, Nutt D, Oretti R, Phillips GD, Robbins TW. The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology 1996;125:285-345.
3. American Psychiatric Association. Diagnostic and statistical manual for the classification of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994.
4. Balster RL, Schuster CR. Fixed interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 1973;20:119-29.
5. Bergman J, Madras BK, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates: III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989;251:150-5.
6. Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989;28:768-72.
7. Brady JV, Lukas SE. Testing drugs for physical dependence potential and abuse liability. In: National Institute on Drug Abuse Research Monograph Series 52. Washington, DC: US Government Printing Office, 1984 (Department of Health and Human Services Publication No. (ADM) 90-1332).
8. Brady JV, Lukas SE, Lamb RJ. Assessing drugs for abuse liability and dependence potential in laboratory primates. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer, 1987. pp. 45-86.
9. Brady JV, Heinz RD, Ator NA. Stimulus functions of drugs and the assessment of abuse liability. Drug Dev Res 1990;20:231-49.
10. Brown WA. Psychologic and neuroendocrine response to methylphenidate. Arch Gen Psychiatry 1977;34:1103-8.
11. Brown WA, Corriveau DP, Ebert MH. Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate. Psychopharmacology 1978;58:189-95.
12. Cardinale V, editor. Drug topics redbook. Montvale, NJ: Medical Economics, 1996. p. 98.
13. Chait LD. Factors influencing the reinforcing and subjective effects of D-amphetamine in humans. Behav Pharmacol 1993;4:191-9.
14. Chait LD. Reinforcing and subjective effects of methylphenidate in humans. Behav Pharmacol 1994;5:281-8.
15. Collins JR, Weeks JR, Cooper MM, Good PI, Russell RR. Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology 1984;82:6-13.
16. Colpaert FC, Niemegeers JE, Janssen PAJ. Discriminative stimulus properties of cocaine: neuropharmacological characteristics as derived from stimulus generalization experiments. Pharmacol, Biochem Behav 1979;10:535-46.
17. Cooper JR. Availability of stimulant medications: nature and extent of abuse and associated harm. Proceedings of diagnosis and treatment of Attention Deficit Hyperactivity Disorder. National Institutes of Health Consensus Statement. Bethesda, MD: NIH, 1998:205-9.
18. Crutchley A, Temlett JA. Methylphenidate (Ritalin) use and abuse. S Afr Med J 1999;89:1076-9.
19. de la Garza R, Johanson CE. Discriminative stimulus properties of intragastrically administered D-amphetamine and pentobarbital in rhesus monkeys. J Pharmacol Exp Ther 1987;243:955-62.
20. de Wit H, Johanson CE. A drug preference procedure for use with human volunteers. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer, 1987. pp. 559-72.
21. Drug Enforcement Administration. Office of Diversion Control, methylphenidate review: eight factor analysis (Washington, DC) DEA.
22. Drug Enforcement Administration: DEA Congressional Testimony by Terrance Woodworth before the Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth and Families. World Wide Web URL: http://www.usdoj.gov/dea/pbs/cngrtest/ct051600.htm. Accessed May 16, 2000.
23. Emmett-Oglesby MW, Wurst M, Lai H. Discriminative stimulus properties of a small dose of cocaine. Neuropharmacology 1983;22:97-101.
24. Eshleman AJ, Henningsen RA, Neve KA, Janowsky A. Release of dopamine via the human transporter. Mol Pharmacol 1994;45:312-6.
25. Evans SM, Johanson CE. Amphetamine-like effects of anorectics and related compounds in pigeons. J Pharmacol Exp Ther 1987;241:817-25.
26. Feussner G. Diversion, trafficking, and abuse of methylphenidate. In: Diagnosis and treatment of Attention Deficit Hyperactivity Disorder National Institutes of Health Consensus Statement. Bethesda, MD: NIH, 1998:201-4.
27. Fischman MW, Mello NK. Testing for abuse liability of drugs in humans. In: National Institute on Drug Abuse Research Monograph Series 92. Washington, DC: US Government Printing Office, 1989 (Department of Health and Human Services Publication No. (ADM) 89-1613).
28. Garland EJ. Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry 1998;37:573-4.
29. Gatley SJ, Volkow ND, Gifford AN, Fowler JS, Dewey SL, Ding YS, Logan J. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology 1999;146:93-100.
30. Glennon RA, Young R. The study of structure-activity relationships using drug discrimination methodology. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer, 1987. pp. 373-90.
31. Glennon R.A., Jarbe T.U.C., Frankenheim J.. Drug discrimination: applications to drug abuse research. In: National Institute on Drug Abuse Research Monograph Series 116. Rockville, MD: US Department of Health and Human Services, 1991 (Public Health Service: Alcohol, Drug Abuse, and Mental Health Administration (DHHS [ADM] 92-1878)).
32. Goudie AJ, Atkinson J, West CR. Discriminative properties of the psychostimulant DL-cathinone in a two lever operant task. Neuropharmacology 1986;25:85-94.
33. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17:485-8.
34. Griffiths RR, Findley JD, Brady JV, Dolan-Gutcher K, Robinson WW. Comparison of progressive-ratio performance maintained by cocaine, methylphenidate and secobarbital. Psychopharmacologia 1975;43:81-3.
35. Heishman SJ, Henningfield JE. Discriminative stimulus effects of D-amphetamine, methylphenidate and diazepam in humans. Psychopharmacology 1991;103:436-42.
36. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Ruddon RW, Gilman AG, editors. Goodman's and Gilman's the pharmacological basis of therapeutics. 9th ed. New York, NY: Pergamon, 1996. pp. 199-250.
37. Huang JT, Ho BT. Discriminative stimulus properties of D-amphetamine and related compounds in rats. Pharmacol, Biochem Behav 1974;2:669-73.
38. Huey LY, Janowsky DS, Judd LL, Roitman NA, Clopton PL, Segal D, Hall L, Parker D. The effects of naloxone on methylphenidate-induced mood and behavioral changes: a negative study. Psychopharmacology 1980;67:125-30.
39. Indiana Resource Prevention Center. Alcohol, tobacco, and other drug use by Indiana children and adolescents Bloomington, IN: Institute for Drug Abuse Prevention, 1999 http://www.drugs.Indiana.edu/drug_stats/youth99/.
40. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug-abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 1991;30:773-5.
41. Jaffe JH, Jaffe FK. Historical perspectives on the use of subjective effects measures in assessing the abuse potential of drugs. In: Fishman MW, Mello NK, editors. Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Research Monograph Series 92. Washington, DC: US Government Printing Office, 1989. pp. 43-72 (Department of Health and Human Services Publication No. (ADM) 89-1613).
42. Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR, editor. Handbook of experimental pharmacology. Berlin: Springer, 1977. pp. 197-258.
43. Jasinski DR, Henningfield JE. Human abuse liability assessment by measurement of subjective and physiological effects. In: Fishman MW, Mello NK, editors. Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Research Monograph Series 92. Washington, DC: US Government Printing Office, 1989. pp. 73-100 (Department of Health and Human Services Publication No. (ADM) 89-1613).
44. Johanson CE, Schuster CR. A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther 1975;193:676-88.
45. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: D-amphetamine. Psychopharmacology 1980;72:275-9.
46. Jones CN, Howard JL, McBennett T. Stimulus properties of antidepressants in the rat. Psychopharmacology 1980;67:111-8.
47. Kamien JB, Woolverton WL. A pharmacological analysis of the discriminative stimulus properties of D-amphetamine in rhesus monkeys. J Pharmacol Exp Ther 1989;248:938-46.
48. Kleven MS, Kamenka JM, Vignon J, Koek W. Pharmacological characterization of the discriminative stimulus properties of the phencyclidine analog, N-[1-(2-benzo(b)thiophenyl)-cyclohexyl]piperidine. Psychopharmacology 1999;145:370-7.
49. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998a;6:367-74.
50. Kollins SH, Shapiro SK, Newland MC, Abramowitz A. Discriminative and participant-rated effects of methylphenidate in children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Exp Clin Psychopharmacol 1998b;6:1-15.
51. Lamb RJ, Griffiths RR. Self-administration in baboons and the discriminative-stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 1990;102:183-90.
52. LeSage MG, Stafford D, Glowa JR. Preclinical research on cocaine self-administration: environmental determinants and their interaction with pharmacological treatment. Neurosci Biobehav Rev 1999;23:717-41.
53. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59:300-5.
54. Levine B, Caplan YH, Kaufman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986;10:209-10.
55. Llana ME, Crismon ML. Methylphenidate: increased abuse or appropriate use? J Am Pharm Assoc 1999;39:526-30.
56. MacDonald EK, Kollins SH. Assessing the reinforcing effects of methylphenidate in children diagnosed with ADHD using a choice procedure. Drug and Alcohol Depend 2000;60:S134.
57. Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Gage HD, Morton TE. Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacol, Biochem Behav 1997;57:477-86.
58. Martin WR, Sloan JW, Sapira JD, Jasiniski DR. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-58.
59. Martin-Iverson MT, Ortmann R, Fibiger HC. Place preference conditioning with methylphenidate and nomifensine. Brain Res 1985;332:59-67.
60. Massello W, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci 1999;44:220-1.
61. McKenna ML, Ho BT. The role of dopamine in the discriminative stimulus properties of cocaine. Neuropharmacology 1980;19:297-303.
62. McNair DM, Lorr M, Droppleman LF. Profile of mood states (manual) San Diego: Educational and Industrial Testing Services, 1971.
63. Melia KF, Spealman RD. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J Pharmacol Exp Ther 1991;258:626-32.
64. Miller TP, Taylor JL, Tinklenberg JR. A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam, and diphenhydramine in abstinent alcoholics. Neuropsychobiology 1988;19:90-6.
65. Mithani S, Martin-Iverson MT, Phillips AG, Fibiger HC. The effects of haloperidol on amphetamine and methylphenidate-induced conditioned place preferences and locomotor activity. Psychopharmacology 1986;90:247-52.
66. Musser CJ, Ahmann FW, Mundt P, Broste SK, Mueller-Rizner N. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 1998;19:187-92.
67. National Institute on Drug Abuse, Community Epidemiology Work Group (CEWG). Epidemiologic trends in drug abuse Washington, DC: NIH, 1995 (DHHS Pub. No.).
68. Nielsen JA, Duda NJ, Mokler DJ, Moore KE. Self-administration of central stimulants by rats, a comparison of the effects of D-amphetamine, methylphenidate and McNeil 4612. Pharmacol, Biochem Behav 1983;20:227-32.
69. Overton DA. Applications and limitations of the drug discrimination method for the study of drug abuse. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer, 1987. pp. 291-340.
70. Parran TV, Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991;151:781-3.
71. Persico AM, Reich S, Henningfield JE, Kuhar MJ, Uhl GR. Parkinsonian patients report blunted subjective effects of methylphenidate. Exp Clin Psychopharmacol 1998;6:54-63.
72. Preston K, Bigelow GE. Subjective and discriminative effects of drugs. Behav Pharmacol 1991;2:293-313.
73. Raskind M, Bradford T. Methylphenidate (Ritalin) abuse and methadone maintenance. Dis Nerv Syst 1975;36:9-12.
74. Risner ME, Jones BE. Self-administration of CNS stimulants by the dog. Psychopharmacologia 1975;43:207-13.
75. Risner ME, Jones BE. Characteristics of unlimited access to self-administered stimulant infusions in dogs. Biol Psychiatry 1976;11:625-34.
76. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-23.
77. Roache JD, Grabowski J, Schmitz JM, Creson DL, Rhoades HM. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychopharmacol 2000;20:61-8.
78. Roehrs T, Papineau K, Rosenthal L, Roth T. Sleepiness and the reinforcing and subjective effects of methylphenidate. Exp Clin Psychopharmacol 1999;7:145-50.
79. Rosen JB, Young AM, Beuthin FC, Louis-Ferdinand RT. Discriminative stimulus properties of amphetamine and other stimulants in lead-exposed and normal rats. Pharmacol, Biochem Behav 1985;24:211-5.
80. Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol, in press.
81. Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in D-amphetamine-trained humans. Exp Clin Psychopharmacol 1998;6:32-44.
82. Rush CR, Essman WD, Simpson CA, Baker RW. Reinforcing and subject-rated effects of methylphenidate and D-amphetamine in non-drug-abusing volunteers. J Clin Psychopharmacol, in press.
83. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996;98:1084-8.
84. Schuster CR, Johanson CE. Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert FC, Balster RL, editors. Transduction mechanisms of drug stimuli. Berlin: Springer, 1988. pp. 161-75.
85. Shearman G, Lal H. Discriminative stimulus properties of pentylenetetrazol and bemegride: some generalization and antagonism tests. Psychopharmacology 1979;64:315-9.
86. Silverman PB, Ho BT. The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): differentiation from amphetamine. Psychopharmacology 1980;68:209-15.
87. Smith BJ, Bickel WK. The novel-response procedure in humans. Pharmacol, Biochem Behav 1999;64:245-50.
88. Smith RC, Davis JM. Comparative effects of D-amphetamine, L-amphetamine, and methylphenidate in man. Psychopharmacology 1977;53:1-12.
89. Stepp LS. A wonder drug's worst side effect, kids turning to easy-to-get Ritalin for a quick - and sometimes deadly - high. The Washington Post. A1, February 5, 1996.
90. Student Net Publishing, LLP. Available at World Wide Web: The Ritalin Racket http://www.student.com/article/ritalin., 1998.
91. Swanson JM, McBurnett K, Wigal T, Pfiffner LJ, et al. Effect of stimulant medication on hyperactive children: a review of reviews. Except Child 1993;60:154-62.
92. Tang AH, Franklin SR. Discriminative stimulus effects of a low dose of apomorphine in the rat. Psychopharmacology 1987;91:61-6.
93. Vogt A. Teens find high in Ritalin, experts say, Suburban schools lock up drug after break ins. The Chicago Tribune. Metro Lake, January 22,1999. p. 1.
94. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Liebermann J, Hitzemann R, Wolf AP. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456-63.
95. Volkow ND, Wang GJ, Gatley SJ, Fowler JS, Ding YS, Logan J, Hitzemann B, Angrist B, Lieberman J. Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology 1996;123:26-33.
96. Volkow ND, Wang GJ, Fowler JS, Logan J, Galley SJ, Hitzemann R, Chen SL, Dewey SL, Pappas N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830-3.
97. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Gatley J, Ding YS, Wong N, Pappas N. Differences in regional brain metabolic responses between single and repeated doses of methylphenidate. Psychiatr Res Neuroimaging 1998;83:29-36.
98. Volkow ND, Fowler JS, Gatley JS, Dewey SL, Wang GJ, Logan J, Ding D, Franceschi D, Gifford A, Morgan A, Pappas N, King P. Comparable changes in synaptic dopamine induced by methylphenidate and cocaine in the baboon brain. Synapse 1999a;31:59-66.
99. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N. Methylphenidate and cocaine have similar in vivo potency to block the dopamine transporters in the human brain. Life Sci 1999b;65:7-12.
100. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Dewey AN, Gifford AN, Pappas N. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J Pharmacol Exp Ther 1999c;288:14-20.
101. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999d;156:19-26.
102. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, Pappas N. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999e;156:1440-3.
103. 2 receptors. J Pharmacol Exp Ther 1999f;291:409-15.
104. Walker MK, Sprague RL, Sleator EK, Ullmann RK. Effects of methylphenidate hydrochloride on the subjective reporting of mood in children with attention deficit disorder. Issues Ment Health Nurs 1988;9:373-85.
105. Ward AS, Haney M, Fischman MW, Foltin RW. Binge cocaine self-administration in humans: intravenous cocaine. Psychopharmacology 1997;132:375-81.
106. Weiner AL. Emerging drugs of abuse in Connecticut. Conn Med 2000;64:19-23.
107. Wilson MC, Hitomi M, Schuster CR. Psychomotor stimulant self-administration as a function of dosage per injection in the rhesus monkey. Psychopharmacologia 1971;22:271-81.
108. Wood DM, Emmett-Oglesby MW. Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology 1988;95:364-8.
109. Yokel RA. Intravenous self-administration: response rates, the effects of pharmacological challenges, and drug preferences. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer, 1987. pp. 1-34.
110. Young R, Glennon RA. Discriminative stimulus properties of (-)ephedrine. Pharmacol, Biochem Behav 1998a;60:771-5.
111. Young R, Glennon RA. Discriminative stimulus effects of S(-)-methcathinone (CAT). A potent stimulant drug of abuse. Psychopharmacology 1998b;140:250-6.